Definitive Assessments
Optivia Delivers FDA Ready Reports
To order our services please call:
650-324-3177, extension 16
Toll Free: 888-OPTIVIA (888-678-4842)
Fax: 650-324-1855.
QUESTIONS?
Speak with one of our transporter specialists about your specific requirements to understand how we could help you and what kind of results you can expect.
CONTACT US:
888-OPTIVIA (888-678-4842)
Substrate Transport Studies
Optivia substrate transport studies assess whether your compound is a substrate of the expressed transporter. Substrates can be vulnerable to becoming unsafe through a drug-drug interaction.
Functional transport of your compound is measured and compared to the control experiment. An increase over control indicates your compound is a transported substrate of the expressed transporter. Substrate activity can also be further confirmed by the addition of one or more inhibitors.
Standard substrate transport screening studies are performed at a single concentration of the test compound.
Full dose response curves are available to calculate the transport kinetics (Km and Vmax) of your compound.
OptiDDI-Substrate™ and OptiDDI-Km™ are recommended for development compounds since they were designed in accordance with the ITC Transporter White Paper and FDA Advisory Committee recommendations.
Optivia substrate transport studies assess whether your compound is a substrate of the expressed transporter. Substrates can be vulnerable to becoming unsafe through a drug-drug interaction.
Functional transport of your compound is measured and compared to the control experiment. An increase over control indicates your compound is a transported substrate of the expressed transporter. Substrate activity can also be further confirmed by the addition of one or more inhibitors.
Standard substrate transport screening studies are performed at a single concentration of the test compound.
Full dose response curves are available to calculate the transport kinetics (Km and Vmax) of your compound.
OptiDDI-Substrate™ and OptiDDI-Km™ are recommended for development compounds since they were designed in accordance with the ITC Transporter White Paper and FDA Advisory Committee recommendations.